CN108474005B - 转位子系统、试剂盒及其用途 - Google Patents

转位子系统、试剂盒及其用途 Download PDF

Info

Publication number
CN108474005B
CN108474005B CN201680071463.4A CN201680071463A CN108474005B CN 108474005 B CN108474005 B CN 108474005B CN 201680071463 A CN201680071463 A CN 201680071463A CN 108474005 B CN108474005 B CN 108474005B
Authority
CN
China
Prior art keywords
promoter
cell
cells
vector
exogenous dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680071463.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108474005A (zh
Inventor
吴琼媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pioneer Biotechnology Co ltd
Original Assignee
Pioneer Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pioneer Biotechnology Co ltd filed Critical Pioneer Biotechnology Co ltd
Publication of CN108474005A publication Critical patent/CN108474005A/zh
Application granted granted Critical
Publication of CN108474005B publication Critical patent/CN108474005B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201680071463.4A 2015-12-14 2016-12-12 转位子系统、试剂盒及其用途 Active CN108474005B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267270P 2015-12-14 2015-12-14
US62/267,270 2015-12-14
PCT/CN2016/109510 WO2017101749A1 (en) 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof

Publications (2)

Publication Number Publication Date
CN108474005A CN108474005A (zh) 2018-08-31
CN108474005B true CN108474005B (zh) 2022-10-21

Family

ID=59055731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071463.4A Active CN108474005B (zh) 2015-12-14 2016-12-12 转位子系统、试剂盒及其用途

Country Status (11)

Country Link
US (1) US11345926B2 (enExample)
JP (1) JP6956416B2 (enExample)
KR (1) KR102249982B1 (enExample)
CN (1) CN108474005B (enExample)
AU (1) AU2016373365B2 (enExample)
CA (1) CA3004665C (enExample)
MX (1) MX380289B (enExample)
MY (1) MY184126A (enExample)
NZ (1) NZ742068A (enExample)
TW (1) TWI609960B (enExample)
WO (1) WO2017101749A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
AU2020290790A1 (en) * 2019-06-11 2022-01-27 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same
JP7693253B2 (ja) * 2021-07-09 2025-06-17 ネオジェンティーシ― コーポレーション トランスポゾンシステムおよびその用途
WO2023060589A1 (zh) * 2021-10-15 2023-04-20 深圳市深研生物科技有限公司 多转座子系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297031A (zh) * 2005-05-14 2008-10-29 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
CN102943092A (zh) * 2012-11-20 2013-02-27 西北农林科技大学 一种通用型PiggyBac转座子转基因载体及其制备方法
CN104884626A (zh) * 2012-11-20 2015-09-02 杰.尔.辛普洛公司 Tal介导的转移dna插入

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
KR20080041146A (ko) * 2007-12-13 2008-05-09 푸단 유니버시티 척추동물에서의 유전자 조작 및 분석을 위한 도구로서의피기백
SG174155A1 (en) 2009-02-25 2011-10-28 Univ Johns Hopkins Piggybac transposon variants and methods of use
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
US10398787B2 (en) * 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
EP3119896B1 (en) 2014-03-21 2022-03-23 The Sydney Children's Hospitals Network (Randwick and Westmead) Stable gene transfer to proliferating cells
CA3246595A1 (en) * 2014-04-09 2025-07-08 Dna Twopointo Inc Enhanced polynucleotide constructs for eukaryotic gene expression
SG11201608393TA (en) * 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297031A (zh) * 2005-05-14 2008-10-29 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
CN102943092A (zh) * 2012-11-20 2013-02-27 西北农林科技大学 一种通用型PiggyBac转座子转基因载体及其制备方法
CN104884626A (zh) * 2012-11-20 2015-09-02 杰.尔.辛普洛公司 Tal介导的转移dna插入

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A versatile, highly efficient, and potentially safer piggyBac transposon system for mammalian genome manipulations;Yaa-Jyuhn James Meir等;《The FASEB Journal》;20130729;第27卷(第11期);第4429页摘要 *

Also Published As

Publication number Publication date
CA3004665A1 (en) 2017-06-22
CA3004665C (en) 2021-08-24
US11345926B2 (en) 2022-05-31
AU2016373365B2 (en) 2021-07-08
JP6956416B2 (ja) 2021-11-02
MY184126A (en) 2021-03-19
MX380289B (es) 2025-03-12
KR20180092989A (ko) 2018-08-20
MX2018007203A (es) 2018-11-12
KR102249982B1 (ko) 2021-05-11
NZ742068A (en) 2023-07-28
TWI609960B (zh) 2018-01-01
WO2017101749A1 (en) 2017-06-22
AU2016373365A1 (en) 2018-05-17
US20180320196A1 (en) 2018-11-08
TW201720926A (zh) 2017-06-16
JP2019503653A (ja) 2019-02-14
CN108474005A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
CN108474005B (zh) 转位子系统、试剂盒及其用途
CN113151215B (zh) 工程化的Cas12i核酸酶及其效应蛋白以及用途
JP6684782B2 (ja) キメラ抗原受容体
US20190241910A1 (en) Genome edited immune effector cells
WO2019173636A1 (en) Cartyrin compositions and methods for use
KR20230029603A (ko) 필수 유전자 녹-인에 의한 선택
KR20220090512A (ko) 액체암의 치료를 위한 조성물 및 방법
WO2016014794A1 (en) Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
EP3359676B1 (en) Transposon system, kit comprising the same, and uses thereof
US20240425830A1 (en) Engineered cas12i nuclease, effector protein and use thereof
CN114164231A (zh) 对细胞中的靶位点进行基因编辑的方法
JP2023521410A (ja) 大型のアデノウイルスペイロードの組み込み
JP7672006B2 (ja) 制御性ｔ細胞を改変するための組成物および方法
EP4544059A1 (en) Compositions and methods for epigenetic regulation of b2m expression
US20250228940A1 (en) Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023138617A1 (zh) 工程化的CasX核酸酶、效应蛋白及其用途
WO2025156492A1 (zh) 转座酶及其用途
WO2025049792A1 (en) Compositions and methods for epigenetic regulation of tgfbr2 expression
CN115803438A (zh) 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列
WO2024059791A1 (en) Large serine recombinases, systems and uses thereof
HK40054104B (en) Engineered cas12i nuclease as well as effector protein and use thereof
HK40054104A (en) Engineered cas12i nuclease as well as effector protein and use thereof
Spielmann et al. GROWTH FACTOR GENE THERAPY IN DIABETIC PIGS: TRANSGENIC KERATINOCYTE TRANSPLANTATION TO FULL-THICKNESS WOUNDS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: England group

Applicant after: Pioneer Biotechnology Co.,Ltd.

Address before: England group

Applicant before: GenomeFrontier Therapeutics, Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20210128

Address after: Taipei City, Taiwan, China

Applicant after: Pioneer Biotechnology Co.,Ltd.

Address before: England group

Applicant before: Pioneer Biotechnology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant